

Serial No. 10/645,784

RECEIVED  
CENTRAL FAX CENTER

JUN 03 2008

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:


Claims 1-28. (Cancelled).

29. (Previously Presented). The process of Claim 46, wherein the gene construct is expressed in an E. coli cell.

30-45. (Cancelled).

46. (Amended). A process for preparing a pharmacologically active compound, which comprises:

- (a) selecting from a peptide phage display library at least one nucleic acid sequence encoding a peptide that modulates the activity of AGP-3, wherein "peptide" refers to molecules of 2 to 40 amino acids;
- (b) preparing a gene construct that encodes comprises at least one said selected peptide sequence and an Fc domain;
- (c) expressing a pharmacologically active compound from the gene construct, wherein the gene construct encodes a compound of the formula



and multimers thereof, wherein:

F<sup>1</sup> is an Fc domain;

X<sup>1</sup> and X<sup>2</sup> are each independently selected from -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>, -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-(L<sup>2</sup>)<sub>d</sub>-P<sup>2</sup>, -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-(L<sup>2</sup>)<sub>d</sub>-P<sup>2</sup>-(L<sup>3</sup>)<sub>e</sub>-P<sup>3</sup>, and -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-(L<sup>2</sup>)<sub>d</sub>-P<sup>2</sup>-(L<sup>3</sup>)<sub>e</sub>-P<sup>3</sup>-(L<sup>4</sup>)<sub>f</sub>-P<sup>4</sup>;

P<sup>1</sup>, P<sup>2</sup>, P<sup>3</sup>, and P<sup>4</sup> are each independently encoded by the selected peptide sequences;

L<sup>1</sup>, L<sup>2</sup>, L<sup>3</sup>, and L<sup>4</sup> are each independently linkers; and  
a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1

- (c) expressing the pharmacologically active compound comprising the Fc-peptide fusion protein from said gene construct; and
- (d) isolating said expressed protein, wherein said isolated protein modulates the activity of AGP-3.

Serial No. 10/645,784


47. (Original). The process of Claim 46, wherein the compound prepared is of the formulae




or



48. (Original). The process of Claim 46, wherein the compound prepared is of the formulae



or



49. (Original). The process of Claim 46, wherein F<sup>1</sup> is an IgG Fc domain.

50. (Original). The process of Claim 46, wherein F<sup>1</sup> is an IgG1 Fc domain.

51. (Original). The process of Claim 46, wherein F<sup>1</sup> comprises the sequence of SEQ ID NO: 2.

Claims 52-62 (Canceled).

63. (Previously Presented). The process of Claim 46 wherein a is 1 and b is 0.

64. (Previously Presented). The process of Claim 46 wherein X<sup>1</sup> is -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-(L<sup>2</sup>)<sub>d</sub>-P<sup>2</sup>.

65. (Previously Presented). The process of Claim 63 wherein X<sup>1</sup> is -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-(L<sup>2</sup>)<sub>d</sub>-P<sup>2</sup>.

66. (Previously Presented). The process of Claim 65 wherein L<sup>1</sup> is (Gly)<sub>5</sub>.

67. (Previously Presented). The process of Claim 65 wherein L<sup>2</sup> is (Gly)<sub>5</sub>.

68. (Previously Presented). The process of Claim 66 wherein L<sup>2</sup> is (Gly)<sub>5</sub>.

69-79. (Canceled).